In conclusion, mutant IDH in patients with AML was associated with increased risk for cardiac dysfunction and a higher prevalence of CAD at the time of AML diagnosis and during treatment with intensive chemotherapy. This evidence concerns the gene IDH1 and acute myeloid leukemia.